Dainippon Sumitomo Pharma Co., Ltd.

Japan Energy Corporation

Sumitomo Dainippon Pharma Co., Ltd.

Masanori Tobe

Yoshiaki Isobe

Haruhisa Ogita

Haruo Takaku

Ayumu Kurimoto

Tetsuhiro Ogino

Osamu Takahashi

Hajime Kawakami

Hitoshi Fujita

Yuso Goto

Yosuke Takanashi

Toshihiko Sone

Katsumi Kubota

Hiroyuki Matsui

Tomoaki Nakamura

Hideyuki Tomizawa

Tomoya Shiro

The present invention provides: an uracil derivative represented by general formula (I) or a physiologically acceptable salt thereof (in the formula, Rrepresents a hydrogen atom, a Calkyl group, a Calkene group or a 3- to 6-membered saturated or 4- to 6-membered unsaturated aliphatic ring group which may contain 1 to 2 hetero atoms independently selected from the group consisting of N, O and S; Rrepresents a hydrogen atom, a halogen atom, a cyano group, &#x2014;NRR, &#x2014;N&#x2550;CHN(CH), or an Calkyl group; Arand Arindependently represent a 5- to 6-membered aromatic ring group which may contain 1 to 3 hetero atoms independently selected from the group consisting of N, O and S; and L represents a 6-membered aromatic ring group which may contain 1 to 4 nitrogen atoms, a pyrazole group, a triazole group, or an imidazole group); and a therapeutic agent or prophylactic agent for various inflammatory diseases associated with elastase, comprises the compound or the like as an active ingredient. 

Uracil derivative and use thereof for medical purposes

A drug for topically administration which is effective as an antiallergic agent. The drug for topically administration contains as an active ingredient an adenine compound represented by the general formula (1): [wherein ring A represents a 6 to 10 membered, mono or bicyclic, aromatic hydrocarbon or a 5 to 10 membered, mono or bicyclic, aromatic heterocycle containing one to three heteroatoms selected among 0 to 2 nitrogen atoms, 0 or 1 oxygen atom, and 0 or 1 sulfur atom; n is an integer of 0 to 2; m is an integer of 0 to 2; R represents halogeno, (un)substituted alkyl, etc.; Xrepresents oxygen, sulfur, NR(Rrepresents hydrogen or alkyl), or a single bond; Yrepresents a single bond, alkylene, etc.; Yrepresents a single bond, alkylene, etc.; Z represents alkylene; and at least one of Qand Qrepresents &#x2014;COOR(wherein Rrepresents (un)substituted alkyl, etc.), etc.] or a pharmaceutically acceptable salt of the compound.

Adenine compound and use thereof

This invention relates to an adenine derivative, a tautomer thereof, or a pharmaceutically acceptable salt thereof represented by general formula (I): wherein X represents NR(wherein Rrepresents a hydrogen atom or Calkyl) or the like; Rrepresents substituted or unsubstituted alkyl or the like; Rrepresents hydroxyl or the like; and Y represents a substituted or unsubstituted aromatic hetero ring or the like. Also, the present invention relates to pharmaceuticals such as an interferon inducer, antiviral agent, anticancer agent, type 2 helper T cell selective immune response inhibitor, antiallergic agent, and immune response modulator comprising the above derivative as an active ingredient.

Adenine derivatives

Type 2 helper T cell-selective immune response suppressors

Disclosed is a hydroquinone derivative or a pharmaceutically acceptable salt thereof, the hydroquinone derivative being represented by formula (I): ##STR1## wherein R.sup.1 is a phenyl group which is unsubstituted or substituted with a substituent or substituents each independently selected from the group consisting of a halogen atom, a C1-4 alkyl group and a C1-4 alkoxy group;

Hydroquinone derivative and pharmaceutical use thereof

Growing community of inventors

Osaka, Japan

Masanori Tobe